सरकार द्वारा केन्द्रीय अनुसंधान संस्थान, विश्वायतन योगाश्रम का अधिग्रहण

@@@2223. **श्री राम नरेश यादव :** क्या स्वास्थ्य और परिवार कल्याण मंत्री यह बताने की कृपा करेंगे कि :

(क) क्या सरकार का ध्यान दिनांक 12 जून 1990 के "दि टाइम्स आफ़ इंडिया" में, केंद्रीय अनुसंधान संस्थान, विश्वायतन योगाश्रम के अधिग्रहण किए जाने के संबंध में प्रकाशित समाचार की ओर दिलाया गया है, यदि हां; तो इस संबंध में सरकार द्वारा अब तक क्या कदम उठाए गए हैं और योगाश्रम का अधिग्रहण किए जाने के क्या कारण हैं ;

(ख) क्या इस आश्रम में योग प्रशिणार्थियों के लिए परीक्षायें लेने की व्यवस्था की गई है ; यदि नहीं, तो इसके क्या कारण हैं ; और

(ग) क्या योग-अध्यापकों को उनके अब तक के वेतन का भुगतान हो चुका है ; यदि नहीं तो इसके क्या कारण है और इस संबंध में क्या कदम उठाए जा रहे हैं ?

स्वास्थ्य एवं परिवार कल्याण मंत्रालय में राज्य मंत्री (श्री रशीद मसूद) : (क) सरकार द्वारा केंद्रीय योग अनुसंधान संस्थान तथा विश्वायतन योगाश्रम के प्रबंध को अधिगृहीत किए जाने के प्रश्न पर स्वास्थ्य और परिवार कल्याण मंत्रालय में सक्रिय रूप से विचार किया जा रहा है । इन संस्थाओं का अधिग्रहण किए जाने के कारण इनमें तथाकथित वित्तीय अनियमितताओं और कुप्रबन्ध से संबंन्धित है ।

(ख) और (ग) विश्वायतन योगाश्रम एक प्राइवट संगठन है और इसके प्रबंधकों ने तालाबंदी घोषित कर रखी है ।

@@@ Previously Unstarred Question No. 1614 Transferred from 21st August, 1990.

Revision of price fixation formula for drugs

2224. SHRIMATI KAILASHPATI:
SHRIMATI PRATIBHA SINGH:

Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) whether it is a fact that consumer groups have pleaded with his Ministry that present formula of price fixation for drugs is wrong;

(b) if so, what are the details thereof;

(c) whether the pricing formula is also being reviewed as a part of the review of the policy;

(d) whether it is a fact that the formula boosts propagation of expensive drugs and fancy packings;

(e) if so, what is the reaction of his Ministry to such a formula and what steps are being taken to check this practice while reviewing the policy.

(f) whether it is a fact that prices of medicines have steeply gone up but wholesale price index does not reflect the correct picture; and

(g) what steps have been taken to change the base year of index?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) and (b) Some suggestions on the subject have been received by this Ministry from the interested groups.

(c) to (g) This forms a part of the review of the drug policy presently being undertaken by the Government.

Findings of Shankaran Committee on drugs

2225. SHRIMATI KAILASHPATI:
SHRIMATI PRATIBHA SINGH:

Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) whether it is a fact that his Ministry has promised revision in norms to the drug industry;

(b) whether it is a fact that norms were studied by Shankaran Committee and that such a study has no basis;

(c) what are the details of findings of the Committee on norms;

(d) whether it is a fact that his Ministry has come across number of errors of omission and commission in the findings of the Committee; and

(e) if so, what are the details thereof and what steps have been taken to review the position and initiate action against the Committee fo mis-representation of facts?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) No, Sir.

(b) and (c) The requisite information has been furnished in reply to Rajya Sabha Unstarred Question No. 1343 answered on 20-8-1990.

(d) and (e) The entire drug policy is under review.

Shortcomings in the findings of the Murthy Committee on drugs

2226. SHRIMATI KAILASHPATI:
SHRIMATI PRATIBHA SINGH:

Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) what was the necessity to appoint Murthy Committee;

(b) what were the basis on which the members of the Committee were appointed and what are the qualifications and experience each enjoys in line with the job assigned to them;

(c) what are the details of the findings of the Committee and what action has been taken thereon;

(d) whether it is a fact that the members of the Committee were appointed in consultation with on approval of the drug industry;